MPR Weekly Dose Podcast #232 — Uplizna gains new approval; Vanrafia approved for proteinuria in IgAN; schizophrenia ER Tx now available; Imcivree shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk
Release Date: 04/11/2025
MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen
MPR Weekly Dose
The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates simplified HIV regimen.
info_outline
MPR News Weekly Dose #255 — Fluoride Supplements Restricted; AAP Leucovorin Statement; At-Home Ultrasound; Kygevvi Approved; Gazyva Lupus Trial Results
MPR Weekly Dose
FDA restrict the sale of unapproved fluoride products; the AAP statement on leucovorin in ASD; at-home prenatal ultrasound; Kygevvi approved; Gazyva reduces SLE disease activity.
info_outline
MPR Weekly Dose #254 — Tranexamic Acid Label Change; New Tezspire Approval; Psychedelic Gains Breakthrough; Oral Semaglutide for MACE Reduction; Gazyva Approved for Lupus
MPR Weekly Dose
Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus.
info_outline
MPR Weekly Dose Podcast #253 — Bipolar I Treatment; Blood-Based Test for Alzheimer Disease; UC Tx Approved for Pediatrics; Rinvoq Expanded; Oral Glucagon-Like Peptide-1
MPR Weekly Dose
New treatment approved for Bipolar I disorder; IBD treatments gain expanded approval; blood-based test for early detection of Alzheimer disease; and an oral glucagon-like peptide-1 treatment continues to show promise.
info_outline
MPR Weekly Dose Podcast #252 — CDC Approves New Immunization Sched; Novel Furosemide Delivery Device; New IPF Treatment Approved; Libtayo approved for CSCC; Breakthrough Therapy for influenza
MPR Weekly Dose
CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; and the FDA grants Breakthrough therapy designation to a novel influenza therapy.
info_outline
MPR Weekly Dose Podcast #251 — Qivigy for Primary Humoral Immunodeficiency; Near Vision Eyedrops; Tremfya Expanded; Meth Intoxication Tx; Alzheimer Disease Tx Fast Tracked
MPR Weekly Dose
New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease.
info_outline
MPR Weekly Dose Podcast #250 — Changes to MMRV Recs; Trump Admin Links Acetaminophen to Autism; Forzinity Accelerated Approval; Huntington Disease Breakthrough; SC Formulation of Keytruda
MPR Weekly Dose
The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington disease; and a new SC formulation of Keytruda gains approval.
info_outline
MPR Weekly Dose Podcast #249 — Device for Asherman Syndrome; Novel Oral GLP-1 Trial Results; Nasal Spray for Edema; Capvaxive in Adolescents; Ocaliva Withdrawn
MPR Weekly Dose
New device approved to prevent intrauterine adhesions; oral GLP-1 receptor agonists assessed in head to head trial; nasal spray formulation of bumetanide gains approval; Capvaxive elicits immune response in children aged 2 to 17 years; and a primary biliary cholangitis treatment is withdrawn from the market.
info_outline
MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated
MPR Weekly Dose
COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari
info_outline
MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated
MPR Weekly Dose
COVID-19 vaccine approvals; CDC leadership in turmoil; orforglipron weight loss trial results; Ixchiq license suspended by FDA; REMS updated for Filspari
info_outlineUplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.